These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 200987)
41. Stainer and Scholte's pertussis medium with an alternative buffer. Lothe RA; Frøholm LO; Westre G; Kjennerud U J Biol Stand; 1985 Apr; 13(2):129-34. PubMed ID: 2860114 [TBL] [Abstract][Full Text] [Related]
42. Placebo-controlled trial of two acellular pertussis vaccines in Sweden--protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet; 1988 Apr; 1(8592):955-60. PubMed ID: 2896826 [TBL] [Abstract][Full Text] [Related]
44. The use of Bordetella pertussis preserved in liquid nitrogen as a challenge suspension in the Kendrick mouse protection test. Novotny P; Brookes JE J Biol Stand; 1975; 3(1):11-29. PubMed ID: 165201 [No Abstract] [Full Text] [Related]
45. Acellular pertussis vaccines in Japan: past, present and future. Watanabe M; Nagai M Expert Rev Vaccines; 2005 Apr; 4(2):173-84. PubMed ID: 15889991 [TBL] [Abstract][Full Text] [Related]
46. [Extraction of the soluble antigens of B. pertussis during cultivation in a fluid nutrient medium]. Igonina IuA; Trofimova NP Zh Mikrobiol Epidemiol Immunobiol; 1969 May; 46(5):133-4. PubMed ID: 4308061 [No Abstract] [Full Text] [Related]
47. Use of glutamic acid to supplement fluid medium for cultivation of Bordetella pertussis. Lane AG Appl Microbiol; 1970 Mar; 19(3):512-20. PubMed ID: 4314842 [TBL] [Abstract][Full Text] [Related]
48. Correlation between mouse intracerebral potency & 50 per cent histamine sensitizing dose of pertussis vaccine. Gupta RK; Sharma SB; Ahuja S; Saxena SN Indian J Med Res; 1989 May; 89():144-9. PubMed ID: 2476391 [TBL] [Abstract][Full Text] [Related]
49. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Tapiainen T; Cherry JD; Heininger U Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771 [TBL] [Abstract][Full Text] [Related]
50. [Cellular and acellular anti-pertussis vaccines]. Locht C Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821 [TBL] [Abstract][Full Text] [Related]
51. An alternative temperature-based histamine-sensitisation test for absence of residual pertussis toxin in acellular pertussis vaccines. Jensen SE; Engelhart Illigen KE; Hasløv KR Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):73-4. PubMed ID: 20223192 [TBL] [Abstract][Full Text] [Related]
52. Improving the cellular pertussis vaccine: increased potency and consistency. Thalen M; van der Ark A; van den Ijssel J; van Straaten I; Jansen D; Beuvery C; Martens D; Tramper J Vaccine; 2008 Jan; 26(5):653-63. PubMed ID: 18155325 [TBL] [Abstract][Full Text] [Related]
53. Histamine shock in mice sensitized with Hemophilus pertussis vaccine. PARFENTJEV IA; GOODLINE MA J Pharmacol Exp Ther; 1948 Apr; 92(4):411-3. PubMed ID: 18911838 [No Abstract] [Full Text] [Related]
54. Appearance of mouse-lethal toxin in liquid cultures of Bordetella pertussis. Lane AG Appl Microbiol; 1968 Sep; 16(9):1400-5. PubMed ID: 4300172 [TBL] [